Patents Assigned to Novartis AG
  • Patent number: 10844068
    Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: November 24, 2020
    Assignee: Novartis AG
    Inventors: Alex Cortez, Timothy Hoffman, Yongkai Li, Tom Yao-Hsiang Wu, Xiaoyue Zhang
  • Patent number: 10844055
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: November 24, 2020
    Assignee: NOVARTIS AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima, Nichola Smith
  • Patent number: 10844002
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Novartis AG
    Inventors: Rohan Eric John Beckwith, Luis Brito, Brian Addison DeChristopher, Gabriel Grant Gamber, Andrew Geall, Thomas Zabawa
  • Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Publication number: 20200338207
    Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.
    Type: Application
    Filed: December 3, 2019
    Publication date: October 29, 2020
    Applicant: NOVARTIS AG
    Inventors: Bernhard Hubert Geierstanger, Weijia Ou, Tetsuo Uno
  • Publication number: 20200335191
    Abstract: The present disclosure relates to uses of computerized behavioral therapy in the treatment of depressive symptoms or depressive disorder associated with multiple sclerosis.
    Type: Application
    Filed: April 13, 2020
    Publication date: October 22, 2020
    Applicants: Pear Therapeutics, Inc., Novartis AG
    Inventors: Michael Brown, Brent Paul Kersanske, Kenneth R. Weingardt, Jillian Christine Ahrens, Seyyed Nassir Ghaemi, Alexandra Kubara, Florian von Raison
  • Patent number: 10799506
    Abstract: The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an advanced moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: October 13, 2020
    Assignee: NOVARTIS AG
    Inventors: Bindhumadhavan Gururajan, Arnaud Grandeury, Rui Costa
  • Patent number: 10800793
    Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: October 13, 2020
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Michael Connolly, David Jonathan Glass, Manuel Mihalic, Andrew William Patterson, Silvio Roggo, Tea Shavlakadze
  • Patent number: 10799454
    Abstract: An improved method for the manufacture of an oil-in water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration, of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: October 13, 2020
    Assignee: NOVARTIS AG
    Inventors: Gottfried Kraus, Robert Eskes
  • Patent number: 10792361
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: October 6, 2020
    Assignee: NOVARTIS AG
    Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
  • Publication number: 20200306244
    Abstract: The present disclosure relates to a Wingless-type (wnt) inhibitor of formula (I) for use in the treatment of fibrosis and some fibrosis mediated disorders such as stiff skin syndrome and systemic sclerosis. The present disclosure also provides a method for the treatment of fibrosis, a pharmaceutical combination comprising a wnt inhibitor of formula (I) and a second active ingredient for use in the treatment of fibrosis and also the use of a wnt inhibitor of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of fibrosis and fibrosis mediated disorders.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 1, 2020
    Applicant: Novartis AG
    Inventors: Jennifer Leslie HARRIS, Peter GERGELY, Jun LIU, Eric SVENSSON
  • Patent number: 10786576
    Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Alexandra Marshall Bruce, Aaron Kanter, Changgang Lou, Aimee Richardson Usera, Jun Yuan, Frederic Zecri
  • Patent number: 10786492
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 29, 2020
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Patent number: 10787480
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Patent number: 10786578
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Patent number: 10786491
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: September 29, 2020
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Publication number: 20200300834
    Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Applicant: Novartis AG
    Inventors: Brian Little, Jennifer Bordeaux
  • Patent number: 10781268
    Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 22, 2020
    Assignee: Novartis AG
    Inventors: David Urech, Leonardo Borras
  • Publication number: 20200292550
    Abstract: The invention relates, in part, to methods of scoring a sample containing tumor tissue from a cancer patient. The score is representative of a spatial proximity between at least one pair of cells, a first member of the at least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Applicant: Novartis AG
    Inventors: Naveen DAKAPPAGARI, Thai TRAN, Brian LITTLE, Ju Young KIM, Jennifer BORDEAUX
  • Patent number: 10774036
    Abstract: The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: September 15, 2020
    Assignee: Novartis AG
    Inventors: Florian Karl Kleinbeck-Riniker, Tobias Kapferer, Hongyong Kim, Jie Ku, Kurt Laumen, Yunzhong Li, Wei Peng, Thomas Ruch, Thierry Schlama, Yao Yang